Corient Private Wealth
STLN

Corient Private Wealth’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Corient Private Wealth’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,500
Closed -$21K – 2053
2022
Q4 		$21K Buy
+12,500
New +$35.1K ﹤0.01% 1668

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Corient Private Wealth's STLN Position: Q1 2023 in Review

Corient Private Wealth sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q1 2023, closing a stake of 12,500 shares — an estimated $21K sold.

Corient Private Wealth first reported a position in STLN in Q4 2022 and held it in 1 quarter. The position peaked at $21K in Q4 2022. 39 funds tracked by Wall St. Rank hold STLN as of Q1 2023.

  • Corient Private Wealth reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Corient Private Wealth sold 12,500 Starling Oncology Institute, Inc. Common Stock shares in Q1 2023, an estimated $21K.
  • Corient Private Wealth first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Corient Private Wealth's Starling Oncology Institute, Inc. Common Stock position peaked at $21K in Q4 2022.
  • 39 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2023.

Based on Corient Private Wealth's 13F filing for Q1 2023, filed 15 May 2023.